PPARγ signaling and emerging opportunities for improved therapeutics

Jun 9, 2016Pharmacological research

PPARγ signaling and new possibilities for better treatments

AI simplified

Abstract

Rosiglitazone activates G protein-coupled receptor 40 (GPR40), which is essential for optimal PPARγ signaling.

  • PPARγ regulates glucose and lipid metabolism, endothelial function, and inflammation.
  • Thiazolidinediones (TZDs) like rosiglitazone are insulin sensitizers but have notable side effects that limit their use.
  • GPR40 activation by rosiglitazone enhances PPARγ-dependent transcription by recruiting necessary co-activators.
  • GPR40 also has the potential to activate proinflammatory pathways that can inactivate PPARγ.
  • Developing ligands that selectively activate PPARγ without stimulating GPR40 may lead to safer therapeutic options.

AI simplified

Full Text

Full text is available at the source.

what lands in your inbox each week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free